Clinical and Experimental Nephrology

, Volume 12, Issue 2, pp 155–158 | Cite as

Metastatic type-2 papillary renal cell carcinoma responded to interleukin-2 therapy: case report

  • Takeo Kosaka
  • Shuji Mikami
  • Akira Miyajima
  • Mototsugu Oya
Case Report
First Online:
Received:
Accepted:

Abstract

This report documents a case of metastatic papillary renal cell carcinoma (PRCC) which successfully responded to interleukin-2 (IL-2) therapy. A 59-year-old male presented with a left renal mass measuring 3.0 cm in diameter and a right adrenal mass measuring 5.0 cm in diameter. He underwent a left partial nephrectomy and a right adrenalectomy. The histological findings revealed pT1bN1M1 type-2 PRCC and metastatic renal cell carcinoma in the right adrenal gland. The patient was given interferon-α (IFN-α) after the operation for 3 months. A CT scan revealed a metastatic nodule measuring 6.0 cm in diameter near the surface of the liver at 4 months after the opereation. The patient was given interleukin-2 (IL-2), 7 × 105 units/day intravenously, for 3 days per week. A CT scan revealed this hepatic nodule to have decreased in size from 6.0 to 4.0 cm after 4 months of IL-2 therapy. However, a new metastatic nodule measuring 6.0 cm in diameter was found which came in contact with the spleen. Next, the patient was given an increased dose of IL-2 from 7 × 105 to 1.4 × 106 units/day intravenously, for 3 days per week. At 9 months of follow-up after the dose escalation, a CT scan revealed a dramatic decrease in the size of these two metastatic nodules to 1.5 and 0.5 cm, respectively. This is a very rare case in that it represents a type-2 PRCC which dramatically responded to low-dose IL-2 therapy.

Keywords

Papillary renal cell carcinoma Interleukin-2 Metastatic renal cell carcinoma 
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Reuter VE, Presti JC Jr. Contemporary approach to the classification of renal epithelial tumors. Semin Oncol 2000;27:124–37.PubMedGoogle Scholar
  2. 2.
    Beck SD, Patel MI, Snyder ME, Kattan MW, Motzer RJ, Reuter VE, et al. Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma. Ann Surg Oncol 2004;11:71–7.CrossRefPubMedGoogle Scholar
  3. 3.
    Kattan MW, Reuter V, Motzer RJ, Katz J, Russo P. A postoperative prognostic nomogram for renal cell carcinoma. J Urol 2001;166:63–7.CrossRefPubMedGoogle Scholar
  4. 4.
    Mai KT, Landry DC, Robertson SJ, Commons AS, Burns BF, Thijssen A, et al. A comparative study of metastatic renal cell carcinoma with correlation to subtype and primary tumor. Pathol Res Pract 2001;197:671–5.CrossRefPubMedGoogle Scholar
  5. 5.
    Motzer RJ, Bacik J, Mariani T, Russo P, Mazumdar M, Reuter V. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 2002;20:2376–81.CrossRefPubMedGoogle Scholar
  6. 6.
    Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol 2000;163:408–17.CrossRefPubMedGoogle Scholar
  7. 7.
    Delahunt B, Eble JN. Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors. Mod Pathol 1997;10:537–44.PubMedGoogle Scholar
  8. 8.
    Upton MP, Parker RA, Youmans A, McDermott DF, Atkins MB. Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy. J Immunother 2005;28:488–95.CrossRefPubMedGoogle Scholar
  9. 9.
    Ronnen EA, Kondagunta GV, Ishill N, Spodek L, Russo P, Reuter V, et al. Treatment outcome for metastatic papillary renal cell carcinoma patients. Cancer 2006;107:2617–21.CrossRefPubMedGoogle Scholar
  10. 10.
    Diner EK, Linehan M, Walther M. Response of papillary renal cell carcinoma in a solitary kidney to high dose interleukin therapy. Int J Urol 2005;12:996–7.CrossRefPubMedGoogle Scholar
  11. 11.
    Nakagawa T, Kami M, Hori A, Kim SW, Murashige N, Hamaki T, et al. Allogeneic hematopoietic stem cell transplantation with a reduced-intensity conditioning regimen for treatment of metastatic renal cell carcinoma: single institution experience with a minimum 1-year follow-up. Exp Hematol 2004;32:599–606.CrossRefPubMedGoogle Scholar
  12. 12.
    Tykodi SS, Warren EH, Thompson JA, Riddell SR, Childs RW, Otterud BE, Leppert MF, Storb R, Sandmaier BM. Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens. Clin Cancer Res 2004;10:7799–811.CrossRefPubMedGoogle Scholar

Copyright information

© Japanese Society of Nephrology 2008

Authors and Affiliations

  • Takeo Kosaka
    • 1
    • 3
  • Shuji Mikami
    • 2
  • Akira Miyajima
    • 1
  • Mototsugu Oya
    • 1
  1. 1.Department of UrologyKeio University School of MedicineTokyoJapan
  2. 2.Department of PathologyKeio University School of MedicineTokyoJapan
  3. 3.Department of UrologyKeio University School of MedicineTokyoJapan

Personalised recommendations